Q2
WAT — Q2 2026 Financial Report Analysis
Waters' revenue more than doubled to $1.645B in its first full quarter with BD's Biosciences and Diagnostics units, with 9% organic constant-currency growth, but purchase accounting drove a GAAP loss of $1.39 a share and adjusted EPS rose just 3% to $3.05 on a much larger share count.